Skip to content

The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Total Knee Arthroplasty

The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Total Knee Arthroplasty

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01261897
Enrollment
40
Registered
2010-12-17
Start date
2011-01-31
Completion date
2011-09-30
Last updated
2011-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Arthroplasty, Postoperative Pain

Keywords

Adductor-Canal-Blockade, postoperative pain, US-guided nerve block, total knee arthroplasty

Brief summary

The objective of this study is to assess the efficacy of Adductor-Canal-Blockade on pain and morphine consumption after total knee arthroplasty. Our hypothesis is that the Adductor -Canal-Blockade is superior to placebo in reducing pain and morphine consumption after total knee arthroplasty.

Interventions

US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml

US-guided Adductor-Canal-blockade with saline

Sponsors

Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Total Knee Arthroplasty in general anaesthesia * ASA 1-3 * BMI 18-40 * Written informed consent

Exclusion criteria

* Can not cooperate to the exam * Do not speak or understand Danish * Drug allergy * Alcohol or drug abuse * Daily consumption of strong opioids

Design outcomes

Primary

MeasureTime frameDescription
Pain during 45 degrees active flexion of the knee1 hour postoperative0-100 mm at a visual analogue scale (VAS), at 1 hour postoperative

Secondary

MeasureTime frameDescription
Pain during rest1-6 hours postoperative0-100 mm at a visual analogue scale (VAS), registered at the intervals 1, 2, 3, 4, 5 and 6 hours postoperative, calculated as the area under the curve (AUC) for the interval 1-6 hours postoperative.
A change in pain score in the ropivacaine group, after activating the block30-60 minutes postoperative0-100 mm at a visual analogue scale (VAS), at 30 and 60 minutes postoperative. A change in pain score in the ropivacaine group compared to the placebo group, after activating the block.
Total morphine consumption30 minutes - 6 hours postoperativeTotal morphine consumption at the interval 30 minutes - 6 hours postoperative.
Pain during 45 degrees active flexion of the knee0-6 hours postoperative0-100 mm at a visual analogue scale (VAS), registered at the intervals 1, 2, 3, 4, 5 and 6 hours postoperative, calculated as the area under the curve (AUC) for the interval 1-6 hours postoperative.
Postoperative vomiting1-6 hours postoperativeNumber of vomiting episodes at the interval 1-6 hours postoperative.
Zofran consumption1-6 hours postoperativeTotal zofran consumption at the intervals 1-6 hours postoperative.
Sedation1-6 hours postoperativeSedation score (0-3) registered at 1, 2, 3, 4, 5 and 6 hours postoperative, calculated as the mean value for the interval 1-6 hours postoperative.
Postoperative nausea1-6 hours postoperativeNausea scores(0-3)registered at 1, 2, 3, 4, 5 and 6 hours postoperative, calculated as mean value for the interval 1-6 hours postoperative.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026